FDA approves breast cancer drug aimed at tackling treatment resistance
Nature Biotechnology reports that the drug is linked with a test to detect ESR1 mutations in circulating tumor DNA.
TLDR
Nature Biotechnology reports FDA approval of a breast cancer drug linked with a test to detect ESR1 mutations in circulating tumor DNA. It describes the drug as part of a wave of new treatments developed to tackle resistance to therapies that target the estrogen receptor.
Combined views
6.7K
1 Source, first seen ago